Category: News from the industry

Canada Must Double Down on Collaboration to Build the Next Generation of Life Sciences Champions

CQDM is joining forces with leaders across Canada’s life sciences ecosystem to reaffirm the importance of fostering an environment that supports innovation, growth, and the commercialization of research-driven breakthroughs. At CQDM, we believe that collaboration is one of Canada’s greatest competitive advantages.This joint call from leaders across the country’s life sciences ecosystem highlights the importance…

Congratulations to Variational AI on their collaboration with Merck!

CQDM congratulates Variational AI (VAI) on announcing a major two-year partnership with Merck, valued at up to USD $349 million. This collaboration aims to accelerate the discovery of new medicines using Enki™, VAI’s cutting-edge generative artificial intelligence platform. CQDM is proud to have played a pivotal role in launching this journey through its Quantum Leap…

Congratulations to Glycovax Pharma for two major advances in the field of vaccines

The CQDM is pleased to highlight the recent achievements of one of its members, Glycovax Pharma, a Montreal-based biopharmaceutical company specializing in glyco-immunology and the development of semi-synthetic vaccines. On one hand, Glycovax is launching large-scale production of the SLA vaccine adjuvant, an innovative compound developed by the National Research Council of Canada (NRC), which…

Call for Applications – Hippocrates Awards 2025 Now Open

The call for applications for the 2025 Hippocrates Awards is officially open. These awards aim to recognize and highlight innovative initiatives in the field of health and social services in Québec. Are you part of an interdisciplinary or cross-sectoral team leading a forward-thinking project? Now is the time to showcase your work! The Hippocrates Awards…

Congratulations to AmacaThera on its upcoming collaboration with a leading global pharmaceutical company!

This partnership was made possible through a CQDM Connect-Pharma call for proposals, an initiative that gives Canadian companies and researchers the opportunity to directly engage with CQDM’s international pharmaceutical members.CQDM plays a unique role as a facilitator of healthcare innovation, going well beyond financial investment. Thanks to its strong connections with major pharmaceutical players and…

Congratulations to Synucure Therapeutics on securing $2.8M in funding!

Congratulations to Synucure Therapeutics, which has just completed a $2.8 million financing round, with 50% of the funding coming from the Government of Québec through Investissement Québec as part of the Impulsion PME program.👏CQDM is proud to have supported this project by acting as an advisor and referring entity, helping facilitate access to this crucial…

The CQDM has joined forces with the RSRI to send a strong message in the face of economic and commercial uncertainties: it is more urgent than ever to take action!

The CQDM is proud to join forces with the 8 other RSRI (Sectoral Industrial Research Groups) to deliver a strong message with one unified voice:Innovation is the key to ensuring the resilience and competitiveness of our Quebec businesses.The collaboration between research and industry is essential to transform ideas into concrete solutions. In a context where…

New funding opportunity for RNA therapies!

Ouverture de l’appel à solutions AReNA est heureux d’annoncer le lancement du premier appel à solutions de la CELLULE. Cette nouvelle approche d’accompagnement et de financement des innovations permettra d’accélérer le développement de technologies hautement prometteuses ayant le potentiel de résoudre certaines problématiques industrielles d’importance limitant actuellement le développement et l’utilisation des thérapies ARN. Les…

CQDM announces the creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

Montréal, le 11 juin 2024 – Le CQDM est fier d’annoncer la création du Réseau de développement et de production de thérapies ARN qui offrira des services de biofabrication en thérapies ARN aux chercheurs académiques et industriels. Mené par l’Institut de recherches cliniques de Montréal (IRCM), l’Université McGill et l’Université Sherbrooke, ce Réseau s’inscrit parmi…

CQDM announces a new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

Cette nouvelle initiative sera mise en œuvre avec l’appui et l’expertise de Axelys Montréal, le 6 juin 2024 – Le CQDM est heureux d’annoncer le lancement d’une nouvelle initiative ambitieuse visant à stimuler l’innovation et l’entrepreneuriat dans la filière de l’ARN thérapeutique au Québec. Menée par Axelys, en collaboration avec plusieurs partenaires, cette initiative s’inscrit…